Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tavaborole in onychomycosis of the toenail
NCT01302119Phase 3Completed
- Sponsor
- Pfizer
- Start
- Feb 2011
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in onychomycosis comparing AN2690 Topical Solution, 5% with Solution Vehicle (2 arms). Primary endpoint: Complete Cure of Target Great Toenail at 52 weeks. Started Feb 2011; status: completed.
02
Drugs
tavaborole
03
Conditions
onychomycosis
Beyond the preview
Go deeper on NCT01302119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01302119.